These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34296282)

  • 1. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
    Tsuzuki S; Kawano S; Fukuokaya W; Mori K; Nishikawa H; Tashiro K; Watanabe D; Uchimoto T; Nishimura K; Yano Y; Murakami M; Koike Y; Hata K; Koide H; Miki J; Abe H; Yamada H; Naruoka T; Sugaya S; Kimura T; Tomita M; Nakajo H; Egawa S
    Jpn J Clin Oncol; 2021 Nov; 51(11):1665-1671. PubMed ID: 34296282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Jiménez N; Garcia de Herreros M; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; García-Esteve S; Rodríguez-Carunchio L; Trias I; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domènech M; Figols M; Carles J; Suárez C; Herrero Rivera D; González-Billalabeitia E; Cívico C; Sala-González N; Ruiz de Porras V; Ribal MJ; Prat A; Mellado B
    Eur Urol Oncol; 2024 Aug; 7(4):954-964. PubMed ID: 38429210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.
    Lim B; Lee W; Kyung YS; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):727-734. PubMed ID: 33948720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
    Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
    Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
    Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
    BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
    Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
    Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
    PeerJ; 2023; 11():e14500. PubMed ID: 36624752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study.
    Omrčen T; Eterović D; Jozić T; Vrdoljak E
    Neoplasma; 2023 Jun; 70(3):476-484. PubMed ID: 37498062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
    Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
    Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8.
    Morozumi K; Mitsuzuka K; Narita S; Takahashi M; Kawamura S; Tochigi T; Arai Y; Hoshi S; Shimoda J; Ishidoya S; Okamoto T; Hatakeyama S; Sakurai T; Tsuchiya N; Ohyama C; Habuchi T; Ito A
    Int J Urol; 2022 Apr; 29(4):324-331. PubMed ID: 35042278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.